Scientists transform protein interaction studies

NewsGuard 100/100 Score

Leading academics at the highly-regarded Astbury Centre for Structural Molecular Biology at the University of Leeds have significantly advanced a method for studying the interactions of proteins, which they say should transform research in this area.

Professor Sheena Radford, Director of the Centre, and a Fellow of the Royal Society, and colleague Professor Andrew Wilson, from the School of Chemistry at Leeds, have led the creation of a new platform for photoinduced-crosslinking.  

Professor Wilson said: “Significant progress has been made in the development of methods for protein crosslinking, a key armament in the toolbox of methods used to study protein complexes and their formation. Our new approach provides a route to study protein complexes and their role in fundamental biological processes within a more compatible timescale."

The scientific community in the UK is among the best equipped in the world already for studying the interactions of proteins, thanks to existing methods like nuclear magnetic resonance, cryo-electron microscopy and x-ray crystallography.

But where these methods are not feasible, our new approach could be used to great effect, and is uniquely suited to the study of rare, transient or dynamic complexes,”

Professor Sheena Radford, Director of the Astbury Centre​

The eight-strong research team, including chemists, structural biologists and engineers have published details of their method in the journal Angewandte Chemie.

Their study describes two new chemical crosslinking mass spectrometry (XL-MS) reagents and a workflow that enables crosslink identification for both well-defined and dynamic protein-protein interactions through photoinduced-crosslinking.

With the XL-MS reagents and a bespoke UV LED irradiation platform the team achieved a maximum crosslinking yield in 10 seconds– about 120 times faster when compared to using conventional mercury lamps for photocrosslinking.

The team has signed a non-exclusive license to sell the new XL-MS reagents through Redbrick Molecular, so they can be used by research groups worldwide.

The University of Leeds has a strong track record of commercializing research and building links with industry.

In addition to the commercialization of individual research outcomes, the University has 200-plus collaborative research projects with business investors, enabling the University to achieve maximum impact from its research, promote private enterprise and enhance public benefit.

Source:

http://www.leeds.ac.uk/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New insights into gas vesicle clustering in bacteria open doors for biomedical applications